Cargando…

The paradox of immunotherapy in NASH-HCC

Detalles Bibliográficos
Autores principales:	Peng, Yao, Wong, Chi Chun, Yu, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192918/ https://www.ncbi.nlm.nih.gov/pubmed/34112767 http://dx.doi.org/10.1038/s41392-021-00654-9

Ejemplares similares

CXCR2 inhibition enables NASH-HCC immunotherapy
por: Leslie, Jack, et al.
Publicado: (2022)

NASH limits anti-tumour surveillance in immunotherapy-treated HCC
por: Pfister, Dominik, et al.
Publicado: (2021)

Somatic mutant clone screening: scan for novel NASH target genes in mouse liver
por: Lan, Tian, et al.
Publicado: (2023)

Mitochondrial Dysfunction in the Transition from NASH to HCC
por: Léveillé, Mélissa, et al.
Publicado: (2019)

Combination therapy for HCC: from CRISPR screening to the design of clinical therapies
por: Wang, Yunguang, et al.
Publicado: (2021)

Pathogenesis from Inflammation to Cancer in NASH-Derived HCC
por: Yu, Simiao, et al.
Publicado: (2022)

An extracellular matrix paradox in myocardial scar formation
por: Cho, Sangkyun, et al.
Publicado: (2020)

The sugar-free paradox: cardiometabolic consequences of erythritol
por: Pafili, Kalliopi, et al.
Publicado: (2023)

The cannabis paradox: contrasting role for marijuana in cardiovascular disease
por: Deng, Lin, et al.
Publicado: (2022)

High hopes and high honours for cancer immunotherapy
por: Häfner, Sophia Julia
Publicado: (2019)

Tumor‐derived microparticles in tumor immunology and immunotherapy
por: Ma, Jingwei, et al.
Publicado: (2020)

Targeting FMRP: A new window for cancer immunotherapy
por: Zhang, Yaguang, et al.
Publicado: (2023)

Targeted prebiotics alter the obese gut microbiome in humans
por: She, Junjun, et al.
Publicado: (2021)

Antigen targeting to dendritic cells: Still a place in future immunotherapy?
por: Stoitzner, Patrizia, et al.
Publicado: (2022)

Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
por: Dongiovanni, Paola, et al.
Publicado: (2021)

Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy [Image: see text]
por: Borst, Jannie, et al.
Publicado: (2021)

Constant regulation for stable CD8 T‐cell functional avidity and its possible implications for cancer immunotherapy
por: Gilfillan, Connie B., et al.
Publicado: (2021)

Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
por: Longo, Miriam, et al.
Publicado: (2021)

Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAK
por: Ge, Chenxu, et al.
Publicado: (2022)

The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products
por: Shao, Gaoxuan, et al.
Publicado: (2022)

Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC
por: Boslem, Ebru, et al.
Publicado: (2023)

HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH
por: De Minicis, Samuele, et al.
Publicado: (2014)

HOX gene regulation in glioma stem cells, mediators of resistance in breast cancer, and paradoxical therapeutic interventions
por: Bogeska, Ruzhica
Publicado: (2021)

Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies
por: Pal Chaudhary, Surendra, et al.
Publicado: (2023)

Chemoimmunotherapy in advanced esophageal squamous cell carcinoma: optimizing chemotherapy regimens for immunotherapy combinations
por: Liu, Zhichao, et al.
Publicado: (2022)

The Role of Oxidative Stress in NAFLD–NASH–HCC Transition—Focus on NADPH Oxidases
por: Gabbia, Daniela, et al.
Publicado: (2021)

Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC
por: Grohmann, Marcus, et al.
Publicado: (2018)

Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC
por: Sydor, Svenja, et al.
Publicado: (2020)

Epigenetic checkpoint blockade: new booster for immunotherapy
por: Wang, Ziqiao, et al.
Publicado: (2021)

A ‘fit’ microbiota to potentiate cancer immunotherapy
por: Rescigno, Maria
Publicado: (2015)

Normalization cancer immunotherapy: blocking Siglec-15!
por: Cao, Guangchao, et al.
Publicado: (2019)

Methionine restriction sensitizes cancer cells to immunotherapy
por: Lu, Weiqin, et al.
Publicado: (2023)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy
por: Pinter, Matthias, et al.
Publicado: (2023)

Likely a matter of time for Amyloid-β immunotherapy
por: Cunha, Andreia
Publicado: (2021)

New strategies for cancer immunotherapy: targeting regulatory T cells
por: Finotello, Francesca, et al.
Publicado: (2017)

Mitochondrial apoptosis: facilitator of NK cell-mediated immunotherapy
por: Ullrich, Evelyn, et al.
Publicado: (2022)

Combined immunotherapy for advanced prostate cancer: Empowering the T cell army
por: Suleman, Sufyan, et al.
Publicado: (2017)

HIF2α Activation in NASH: A New Force Pushing Toward HCC
por: Clavería-Cabello, Alex, et al.
Publicado: (2021)

A maternal high-fat diet induces fetal origins of NASH-HCC in mice
por: Takiyama, Takao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k7lgbhji1in0o578catokp12po